國家衛生研究院 NHRI:Item 3990099045/16878
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12500/13673 (91%)
造访人次 : 2477451      在线人数 : 106
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/16878


    题名: Adverse effects of tyrosine kinase inhibitors on glucose and lipid metabolism in patients with chronic myeloid leukemia
    作者: Huang, RY;Tsai, HJ;Hsieh, KP;Chen, LT;Yang, YH
    贡献者: National Institute of Cancer Research
    摘要: Background: The development of tyrosine kinase inhibitors (TKIs) significantly improved the prognosis of chronic myeloid leukemia (CML) patients. Adverse effects following long-term treatment are of concern; especially, cardiovascular events associated abnormal glucose-lipid metabolism. Objectives: This retrospective cohort study investigates the onset of high hemoglobin A1C (HbA1C), hypercholesterolemia, hypertriglyceridemia, and hyper-low density lipoprotein (LDL)-cholesterolemia in the patients treated with first-line TKI. Methods: CML patients aged over 20 years who had related laboratory data in the 6 months prior to the first-line TKI and within one year after TKI were selected. We extracted information from Taiwan National Health Insurance Database and laboratory data (2015–2020). Patients with other cancers history at baseline were excluded, and they were further grouped by the first-line TKI including imatinib, dasatinib and nilotinib. Time-to-event analysis and multivariable Cox regression was performed to analyze the probability of laboratory data over high cut-off values, including high HbA1C (≥ 6.5 %), hypercholesterolemia (≥ 240 mg/dL), hypertriglyceridemia (≥ 200 mg/dL), and hyper-LDL-cholesterolemia (≥ 160 mg/dL). Death, treatment discontinuation, switched to another TKI or the end of 1-year follow-up period were considered censored. Results: Nilotinib (N) users had higher risk than dasatinib (D) and imatinib (I) users in terms of hypercholesterolemia (N vs. I, hazard ratio, HR, [95% CI] = 3.90 [1.71–8.88]; N vs. D, HR = 2.60 [1.50–4.53]), hyper-LDL-cholesterolemia (N vs. I, HR = 2.91 [1.16–7.31]; N vs. D, HR = 2.15 [1.14–4.05]) and high HbA1C level (N vs. I, HR = 2.38 [1.50–3.78]; N vs. D, HR = 2.14 [1.39–3.28]). In patients without history of hyperlipidemia (N vs. I, HR = 7.61 [1.61–35.98]; N vs. D, HR = 4.33 [1.96–9.59]), without history of ischemic heart disease (N vs. I, HR = 4.36 [1.74–10.90]; N vs. D, HR = 2.76 [2.53–4.99]) or without diabetes (N vs. I, HR = 5.38 [1.87–15.47]; N vs. D, HR = 3.09 [1.67–5.71]), significantly higher risks of hypercholesterolemia were found in the nilotinib group. There was no significant difference for hypercholesterolemia onset in those with histories mentioned above. In patients with history of diabetes (N vs. I, HR = 2.3 [1.43–3.69]; N vs. D, HR = 2.18 [1.39–3.41]), significantly higher risks of high HbA1C level were found in the nilotinib group. No significant difference for high HbA1C level was found in those without diabetes history. Conclusions: Compared with imatinib and dasatinib, nilotinib is more likely to present adverse effects on blood glucose and lipids profile. Therefore, the selection of TKIs would need to consider patient's baseline comorbidity history.
    日期: 2024-11
    關聯: Pharmacoepidemiology and Drug Safety. 2024 Nov;33:165-166.
    Link to: http://dx.doi.org/10.1002/pds.5891
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1053-8569&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001407925901079
    显示于类别:[楊奕馨] 會議論文/會議摘要
    [蔡慧珍] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI001407925901079.pdf78KbAdobe PDF13检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈